Cooperative Agreement UG3CA290451
Award Date
9/9/24
Completion Date
8/31/26
Dollars Obligated
$1.5M
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Cooperative Agreement
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $490,381 to The Pennsylvania State University to develop phase-changing peptide nanoemulsion (NPEP) contrast agents for deep tissue ultrasound imaging of adoptive cellular immunotherapies. The goal is to create NPEP agents that can be rapidly internalized and persist within macrophages, enabling real-time and long-term monitoring of macrophage...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director (CFDA 93.310 - Trans-NIH Research Support) provides $406,249 to the Trustees of the University of Pennsylvania to investigate how chimeric antigen receptor (CAR) T cell therapy can be improved for treating solid tumors. The primary goals are to: Define the tumor and stromal features that influence CAR T cell infiltration and function. Determine the impact of CAR T cell functional profile on...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research Grant Program (CFDA 93.395), awarded a $398,997 Project Grant to Immunogenik, Inc. in Gainesville, Florida. The grant supports the development and evaluation of a "3-in-1" Chimeric Antigen Receptor (CAR) T-cell therapy to enhance cancer treatment. The project aims to overcome limitations of current cancer therapies by targeting tumor-associated myeloid cells, which play a key role in cancer...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Trustees of the University of Pennsylvania is focused on engineering a protein therapeutic to limit the transformation of the patient's own anti-tumor autoantibodies into highly potent T cell-redirecting antibodies, specifically within the tumor microenvironment. The $216,682 award, effective March 1, 2025 through February 28, 2027, aims to optimize the engineered protein therapeutic...
This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
The National Cancer Institute (NCI) awarded a $619,628 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The funding will support the development and validation of an autologous mouse model to study immune system interactions with glioblastoma, a type of brain cancer. The goal is to create a humanized mouse system that incorporates patient-derived tumor...
The National Cancer Institute (NCI) awarded a $798,512 Project Grant under CFDA 93.395 - Cancer Treatment Research to Luminary Therapeutics, Inc., a small disadvantaged business, to develop an allogeneic gamma/delta armored dual-targeting chimeric antigen receptor (CAR) T-cell therapy to treat epithelial ovarian carcinoma. The project aims to address key challenges with CAR T-cell therapies against solid tumors, including antigen escape and the immunosuppressive tumor microenvironment, through...
The Project Grant award R01CA287491, totaling $720,416, was provided by the National Cancer Institute (NCI) under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The award aims to develop a novel "theranostic" (therapeutic and diagnostic) approach using chimeric antigen receptor (CAR) T-cell therapy for the treatment of neuroendocrine prostate cancer (NEPC). The key products and services to be delivered include: Evaluating the therapeutic efficacy of...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $218,089 to the University of California, Santa Barbara to develop and evaluate a novel Chimeric Antigen Receptor Macrophage (CAR-M) immunotherapy targeting triple-negative breast cancer (TNBC). The key goals are to: 1) Evaluate the specificity, efficacy, and impact on angiogenesis of an anti-CSPG4 Rac-enhanced CAR-M (RACE-CAR-M) therapy using in vivo chicken chorioallantoic membrane...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $452,540 to the Sloan-Kettering Institute for Cancer Research to develop a novel T-cell imaging paradigm that will enable real-time monitoring of endogenous T-cell trafficking, tumor targeting, and persistence in patients with multiple myeloma undergoing bispecific T-cell engager antibody (BiTEA) treatments. The goal is to better understand mechanisms of therapy...